Drug Profile


Alternative Names: Dobupal; Efexor XR; Effexor; Effexor XR; Elafax; WY 45030; WY 45651; WY 45655

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Antidepressants; Anxiolytics; Cyclohexanols; Dimethylamines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Generalised anxiety disorder; Major depressive disorder; Panic disorder; Social phobia

Most Recent Events

  • 01 Jul 2016 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT02637193)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2014 Pfizer completes a phase III trial in Major depressive disorder in Japan (NCT01441440)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top